STING Pathway Activation: The Missing Link between Genomic Instability and Antitumor Immunity in Osteosarcoma
Institution:
University of California San Francisco
Researcher(s):
Elizabeth Young, MD
Grant Type:
Young Investigator Grants
Type of Childhood Cancer:
Osteosarcoma
Project Description:
Osteosarcoma is a bone tumor occurring most often in children and young adults. These patients have a 5-year survival rate of less than 20% if the cancer has spread to distant sites at the time of diagnosis. Unfortunately, the remaining 80% of these patients are suspected to have spread of the cancer which is undetectable. The treatment strategy for this disease has not seen significant improvement in 30 years, and there is no specific treatment to target tumors that have spread throughout the body. These distant tumors, particularly those in the lung, are responsible for causing the death of most patients with osteosarcoma. Therefore, understanding how and why these tumors spread to distant sites and learning how to target them is vital to extending the lives of patients. New treatments to be used concurrently with the standard chemotherapy to help prevent the cancer from spreading are desperately needed in pediatric osteosarcoma.